Mr. Ron Nagar reports

TEMPRAMED GRANTED U.S. PATENT FOR PEN AGNOSTIC, VIVI CAP SMART(TM) FURTHER STRENGTHENS GLOBAL INTELLECTUAL PROPERTY POSITION

Tempramed Technologies Ltd.'s U.S. patent application No. 18/264,059 has now been formally granted by the U.S. Patent Office as patent 12,746,342.

The patent, filed on Aug. 2, 2023, was granted on Sept. 29, 2026. The patent includes claims covering key aspects of the company's first of its kind cap adaptable for use with different types of injection pens, VIVI Cap Smart, which was launched earlier this year.

Without limiting the scope of the patent, it includes core elements of Tempramed's proprietary thermal-insulation and smart-monitoring architecture, while being pen agnostic

Being pen agnostic position VIVI Cap Smart as a differentiated platform at the intersection of home health, smart refrigeration and the connected medical-device ecosystem. The innovation supports Tempramed's strategy to provide protection and connectivity to all injection devices for home care wearables and artificial-intelligence platforms.

"The formal grant of our U.S. patent represents a significant milestone in Tempramed's global intellectual property strategy," said Ron Nagar, chief executive officer of Tempramed. "The U.S. is one of the most influential markets globally for advanced healthcare solutions, home care and health and wellness applications. Securing patent protection in this jurisdiction meaningfully strengthens our position and supports the expansion of our comprehensive product portfolio across America."

About Tempramed Technologies Ltd.

Tempramed Technologies develops patented medication temperature protection solutions for people using insulin, GLP-1 therapies, epinephrine auto-injectors and other temperature-sensitive medications. Its commercial portfolio includes VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med. Tempramed is expanding through pharmacy networks, health care institutions, specialist distributors and digital health channels.

We seek Safe Harbor.